AEROSOL FORMULATION FOR THE INHALATION OF BETA AGONISTS

• US 20080041370A1
• Filed: 08/16/2007
• Published: 02/21/2008
• Est. Priority Date: 08/18/2006
• Status: Abandoned Application

• Current Assignee: Kirsten Radau, Michael Aven, Rainer Weitzel
• Original Assignee: Kirsten Radau, Michael Aven, Rainer Weitzel
• Inventors: WEITZEL, Rainer, AVEN, Michael, RADAU, Kirsten
• Application Number:
  US11/839,817
• Publication Number:
  US 20080041370A1
• Time in Patent Office: Days
• US Class Current: 128/200.23
• CPC Class Codes: A61K 31/538 ortho- or peri-condensed with carbocyclic ring systems
• CPC Class Codes: A61K 31/565 not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• CPC Class Codes: A61K 9/008 comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14

Abstract

The present invention relates to a propellant-free aerosol formulation which contains one or more compounds of general formula 1,

wherein the groups R¹, R², R³ and X⁻ may have the meanings indicated in the claims and in the specification, and one other active substance 2, for inhalation.

Claims

1. Medicament formulation comprising:

as active substance one or more compounds of general formula 1

wherein

R¹ denotes hydrogen, C_1-4-alkyl, O—

C_1-4-alkyl or halogen;

R² denotes hydrogen, C_1-4-alkyl, O—

C_1-4-alkyl or halogen;

R³ denotes hydrogen, C_1-4-alkyl, O—

C_1-4-alkyl, halogen, OH, —

O—

C_1-4-alkylene-COOH or O—

C_1-4-alkylene-COO—

C_1-4-alkyl;

X⁻

denotes a mono- or polysubstituted negatively charged anion;

an active substance 2 selected from budesonide, beclomethasone, fluticasone and ciclesonide, or a metabolite thereof; and

at least one pharmacologically acceptable acid or a pharmacologically acceptable buffer system.

2. Medicament formulation according to claim 1, wherein said mono- or polysubstituted negatively charged anion is chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, benzoate, citrate, salicylate, trifluoroacetate, fumarate, tartrate, oxalate, succinate, benzoate or p-toluenesulphonate.

3. Medicament formulation according to claim 1, further comprising:

pharmacologically acceptable excipients; and

ethanol or a mixture of water and ethanol as the solvent.

4. Medicament formulation according to claim 1, wherein one or more said active substances is in the form of the tautomers, enantiomers, mixtures of the enantiomers, racemates, solvates or hydrates thereof.

5. Medicament formulation according to claim 1, wherein

R¹ denotes hydrogen, methyl, ethyl, fluorine or chlorine;

R² denotes hydrogen, methyl, ethyl, fluorine or chlorine;

R³ denotes hydrogen, methyl, ethyl, propyl, OH, methoxy, ethoxy, fluorine, chlorine, bromine, O—

CH₂—

COOH, O—

CH₂—

COOmethyl or O—

CH₂—

COOethyl, —

O—

CH₂—

CH₂COOH, O—

CH₂—

CH₂COOmethyl or O—

CH₂—

CH₂COOethyl, —

O—

CH₂—

CH₂—

CH₂COOH, O—

CH₂—

CH₂—

CH₂COOmethyl or —

O—

CH₂—

CH₂—

CH₂COOethyl;

X⁻

denotes a mono- or polysubstituted negatively charged anion.

6. Medicament formulation according to claim 5, wherein said mono- or polysubstituted negatively charged anion is chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, benzoate, citrate, salicylate, trifluoroacetate, fumarate, tartrate, oxalate, succinate, benzoate or p-toluenesulphonate.

7. Medicament formulation according to claim 5, wherein one or more said active substances is in the form of the tautomers, enantiomers, mixtures of the enantiomers, racemates, solvates or hydrates thereof.

8. Medicament formulation according to claim 1, wherein

R¹ denotes hydrogen or methyl;

R² denotes hydrogen or methyl;

R³ denotes methyl, OH, methoxy, fluorine, chlorine, bromine, O—

CH₂—

COOH or —

O—

CH₂—

COOethyl;

X⁻

denotes a mono- or polysubstituted negatively charged anion selected from chloride, bromide, sulphate, methanesulphonate, maleate, acetate, benzoate, citrate, salicylate, trifluoroacetate, fumarate, tartrate and succinate.

9. Medicament formulation according to claim 8, wherein

R¹ denotes hydrogen.

10. Medicament formulation according to claim 8, wherein

R² denotes hydrogen.

11. Medicament formulation according to claim 8, wherein one or more said active substances is in the form of the tautomers, enantiomers, mixtures of the enantiomers, racemates, solvates or hydrates thereof.

12. Medicament formulation according to claim 1, wherein the active substance 2 is budesonide or ciclesonide, or a metabolite thereof.

13. Medicament formulation according to claim 12, wherein said active substance 2 is in the form of the tautomers, enantiomers, mixtures of the enantiomers, racemates, solvates or hydrates thereof.

14. Medicament formulation according to claim 1, wherein the pharmacologically acceptable acid is selected from the inorganic acids hydrochloric acid, phosphoric acid, hydrobromic acid, nitric acid and sulphuric acid or from the organic acids ascorbic acid, citric acid, malic acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid, propionic acid, sorbic acid, benzoic acid, methanesulphonic acid and benzenesulphonic acid.

15. Medicament formulation according to claim 1, wherein the pharmacologically acceptable buffer system is a citrate buffer, an acetate buffer or a phosphate buffer.

16. Medicament formulation according to claim 1, wherein the pH of said formulation is 2.0 to 6.5.

17. Medicament formulation according to claim 1, wherein the content of 1′

and 2 independently of one another is about 0.1 to 6000 mg per 100 ml solution in each case.

18. Medicament formulation according to claim 1, wherein said formulation comprises a complexing agent as a further pharmacologically acceptable excipient.

19. Medicament formulation according to claim 18, wherein the content of said complexing agent is 0.1 to 50 mg per 100 ml solution.

20. Medicament formulation according to claim 1, wherein said formulation comprises an antioxidant as a further pharmacologically acceptable excipient.

21. Medicament formulation according to claim 1, wherein said formulation comprises as a further pharmacologically acceptable excipient an antioxidant selected from ascorbic acid, propylgallate, butylhydroxyanisol, butylhydroxytoluene, tert-butylhydroxyquinone, tris(2,4-di-tert-butylphenyl)phosphite and tetrakis[methylene(3,5-di-tert-butylhydroxyhydrocinnamate)]methane, tocopherol, naringenin and resveratrol.

22. Medicament formulation according to claim 1, wherein said formulation comprises a mixture of water and ethanol as solvent.

23. Medicament formulation according to claim 1, wherein said formulation comprises benzylalcohol, γ

-butyrolactone or diethyleneglycol monoethylether as co-solvent.

24. Medicament formulation according to claim 22, wherein said formulation comprises as solvent a mixture of water and ethanol in which the percentage amount of ethanol by volume is in the range between 30 and 99% ethanol.

25. Medicament formulation comprising:

as active substance a free base of formula 1′

wherein the groups R¹, R² and R³ may have the meanings given in claim 1;

an active substance 2 selected from budesonide, beclomethasone, fluticasone and ciclesonide, or a metabolite thereof; and

at least one pharmacologically acceptable acid.

26. Medicament formulation according to claim 25, further comprising:

pharmacologically acceptable excipients; and

ethanol or a mixture of water and ethanol as the solvent.

27. Medicament formulation according to claim 25, wherein one or more said active substances is in the form of the tautomers, enantiomers, mixtures of the enantiomers, racemates, solvates or hydrates thereof.

28. Medicament formulation according to claim 27, wherein the active substance 2 is budesonide or ciclesonide, or a metabolite thereof.

29. Medicament formulation according to claim 28, wherein one or more of said active substances is in the form of the tautomers, enantiomers, mixtures of the enantiomers, racemates, solvates or hydrates thereof.

30. A method of treating respiratory complaints, said method comprising administering to a patient in need thereof a therapeutically effective amount of a medicament formulation according to claim 1.

31. Inhalation kit consisting of a medicament formulation according to claim 1 and an inhaler suitable for nebulising said medicament formulation.

32. Inhalation kit according to claim 31, wherein the inhaler is a Respimat®

.